News | January 31, 2022
Pharma industry seeks fiscal support to drive innovation
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The country is sixth among the most affected countries by active cases
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Ram’s appointment follows the launch of the CDI India division in October 2021.
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Subscribe To Our Newsletter & Stay Updated
